ERBB2 and breast cancer: In contrast, a study that aimed to assess whether trastuzumab decreased the detection rate of CTCs in women with high-risk, HER-2 non-amplified, early BC analyzed 1318 HER-2-negative patients after adjuvant treatment and screened for CTCs in the blood.